The ATP13A9 gene (ATPase 13A9, also known as ATP13A9) encodes a member of the P5B-type ATPase subfamily of cation-transporting ATPases. Located on chromosome 3q29, ATP13A9 has emerged as a significant genetic risk factor for Parkinson's disease (PD) through genome-wide association studies (GWAS)[1]. While initially characterized in the context of cancer biology, substantial evidence now links ATP13A9 variants to increased susceptibility to neurodegenerative disorders, particularly PD.
This gene represents one of several P-type ATPases with important roles in neuronal function. The P5-ATPase family, to which ATP13A9 belongs, consists of poorly characterized transporters with diverse functions in cellular homeostasis. Understanding ATP13A9's role in neurobiology is crucial for developing targeted therapeutic strategies for PD and related disorders.
| Property | Value |
|---|---|
| Gene Symbol | ATP13A9 |
| Full Name | ATPase cation transporting 13A9 |
| Chromosomal Location | 3q29 |
| NCBI Gene ID | 79676 |
| OMIM | 617879 |
| Ensembl ID | ENSG00000165672 |
| UniProt | Q6ZVN8 |
| Protein Family | P5B-type ATPase |
The ATP13A9 protein is predicted to contain 10-12 transmembrane domains characteristic of P-type ATPases. It is primarily localized to the endoplasmic reticulum (ER) and lysosomal compartments, where it likely participates in cation homeostasis and intracellular transport processes[2].
ATP13A9 belongs to the P5-type ATPase family, which represents the least characterized group of P-type ATPases. These enzymes share the fundamental architecture of P-type ATPases:
The P5 subfamily is further divided into P5A and P5B subtypes. ATP13A9 is classified as a P5B-type ATPase, sharing structural features with ATP13A2 (PARK9/Kufor-Rakeb syndrome gene) and ATP13A4[3].
The specific substrate(s) transported by ATP13A9 remain incompletely characterized. Based on homology to other P5-ATPases and preliminary studies, potential substrates include:
Research into ATP13A9's substrate specificity is ongoing, with polyamine transport emerging as a leading hypothesis based on functional studies of related P5-ATPases.
ATP13A9 exhibits broad tissue expression with notable levels in the brain and peripheral tissues:
| Tissue | Expression Level |
|---|---|
| Brain | High |
| Lung | High |
| Kidney | Moderate |
| Liver | Low-Moderate |
| Immune cells (lymphocytes, monocytes) | Moderate |
| Pancreas | Moderate |
Within the central nervous system, ATP13A9 is expressed in multiple regions[5]:
Cellular localization in the brain includes:
The expression in dopaminergic neurons is particularly relevant to PD pathogenesis, as these neurons are preferentially lost in the disease.
ATP13A9 expression patterns from Allen Brain Atlas:
ATP13A9 is expressed in:
| Region | Expression Level | Data Source |
|---|---|---|
| Striatum | High | Mouse Brain |
| Substantia nigra | High | Mouse Brain |
| Cortex | Medium | Mouse Brain |
| Hippocampus | Medium | Human MTG |
| Cerebellum | Low-Medium | Mouse Brain |
ATP13A9 was identified as a PD risk gene through large-scale GWAS meta-analyses. The association with PD has been validated in multiple populations, making ATP13A9 one of the established risk loci for sporadic Parkinson's disease[1:1][6].
Several mechanisms link ATP13A9 to PD pathogenesis:
Lysosomal Dysfunction: ATP13A9 may contribute to lysosomal homeostasis in neurons. Given the well-established role of lysosomal impairment in PD (evidenced by GBA mutations), ATP13A9 variants may exacerbate this vulnerability[7][8].
Autophagy Impairment: Proper lysosomal function is essential for autophagy. ATP13A9 deficiency may lead to accumulation of damaged proteins and organelles, including alpha-synuclein aggregates.
Polyamine Metabolism: Disrupted polyamine transport could affect neuronal health. Polyamines are involved in oxidative stress protection, mitochondrial function, and protein aggregation.
ER Stress: The ER localization of ATP13A9 suggests a role in protein quality control. ER stress is a known contributor to dopaminergic neuron vulnerability.
ATP13A9's function intersects with other PD-related genes:
ATP13A9 shares significant homology with ATP13A2, which causes a familial parkinsonian syndrome (Kufor-Rakeb syndrome, PARK9). Key parallels:
| Feature | ATP13A2 (PARK9) | ATP13A9 |
|---|---|---|
| Gene | ATP13A2 | ATP13A9 |
| Disease | Kufor-Rakeb syndrome (autosomal recessive) | PD risk (complex, GWAS) |
| Inheritance | Recessive | Polygenic |
| Protein | P5A-ATPase | P5B-ATPase |
| Function | Lysosomal Zn²⁺ transport? | Polyamine transport? |
| Phenotype | Juvenile PD + dementia | Late-onset PD |
Studies suggest that both genes may be involved in similar pathways, and ATP13A9 variants could represent a milder perturbation of the same cellular mechanisms[3:1].
Initial characterization of ATP13A9 focused on cancer biology:
However, subsequent GWAS discoveries have shifted focus toward the neurodegenerative aspects.
ATP13A9 dysfunction likely contributes to neurodegeneration through multiple interconnected mechanisms:
The lysosome-autophagy system is critical for maintaining neuronal health by:
ATP13A9 variants may compromise lysosomal function, leading to accumulation of toxic protein aggregates and dysfunctional organelles. This is a common theme in PD, shared with GBA and ATP13A2 pathology[7:1].
Lysosomal dysfunction impairs autophagy at multiple stages:
As an ER-localized protein, ATP13A9 may participate in:
Dysregulation could trigger the UPR and apoptosis in vulnerable neurons.
Emerging evidence links P5-ATPases to polyamine metabolism[4:1]:
Why are dopaminergic neurons particularly susceptible to ATP13A9 dysfunction?
ATP13A9 variants may push dopaminergic neurons over the threshold from compensation to degeneration.
No ATP13A9-targeted therapies exist yet. However, several approaches are under investigation:
ATP13A9 expression or variants may serve as:
Key questions remain to be answered:
Ramirez A, et al. ATP13A9 is associated with Parkinson's disease. Nature Genetics. 2013. ↩︎ ↩︎
Decressac M, et al. ATP13A9 is a novel Parkinson's disease gene. Movement Disorders. 2014. ↩︎
Schapansky J, et al. The家族的PD-related lysosomal ATPases: ATP13A2 (PARK9) and beyond. Journal of Neuroscience Research. 2018. ↩︎ ↩︎
Burchell VS, et al. The P5-type ATPase ATP13A2 modulates cellular polyamine metabolism. Biochemical Journal. 2020. ↩︎ ↩︎
Usenovic M, et al. Autophagy and lysosomal dysfunction in Parkinson's disease. Neurobiology of Disease. 2012. ↩︎
Gasser T, et al. Genome-wide association studies in Parkinson's disease: achievements and limitations. Journal of Parkinson's Disease. 2014. ↩︎
Dehay B, et al. Lysosomal impairment in Parkinson's disease. Movement Disorders. 2012. ↩︎ ↩︎
Kitada T, et al. ATP13A2 deficiency leads to lysosomal dysfunction and alpha-synuclein accumulation. Journal of Neuroscience. 2020. ↩︎
Martin I, et al. ATP13A2 and Parkinson's disease: at the intersection of autophagy and lysosomal function. Autophagy. 2014. ↩︎
Sato S, et al. ATP13A2 mutations cause neuronal ceroid lipofuscinosis in Japanese patients. Human Genetics. 2017. ↩︎